The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen
about
HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in MicePreclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.Recombinant BCG vaccines: molecular features and their influence in the expression of foreign genes.
P2860
The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The use of directed evolution ...... g a modified HIV-1 Gag antigen
@ast
The use of directed evolution ...... g a modified HIV-1 Gag antigen
@en
type
label
The use of directed evolution ...... g a modified HIV-1 Gag antigen
@ast
The use of directed evolution ...... g a modified HIV-1 Gag antigen
@en
prefLabel
The use of directed evolution ...... g a modified HIV-1 Gag antigen
@ast
The use of directed evolution ...... g a modified HIV-1 Gag antigen
@en
P2093
P2860
P1433
P1476
The use of directed evolution ...... g a modified HIV-1 Gag antigen
@en
P2093
Enid Shephard
Helen Stutz
Nicola Douglass
Nyasha Chin'ombe
Rosamund Chapman
Thandi Mgwebi
William R Bourn
P2860
P304
P356
10.1371/JOURNAL.PONE.0103314
P407
P577
2014-07-25T00:00:00Z